+15%, Cetaphil's Parent Company Gained $1.9 billion in H1
- Chaileedo Press
- Sep 5, 2022
- 2 min read
The first half of the year was particularly strong for the Cosmetic Injectables and Dermatology product categories at Galderma.
Recently, the parent company of the Cetaphil brand and leading global skin health care company, Galderma, announced its 2022 interim financial report, showing net sales of $1.914 billion, up 15% year-over-year.
The first half of the year was particularly strong for Galderma's cosmetic injectables and dermatology product categories, which grew 32% and 31% respectively at constant exchange rates, according to the report. It believes that demand for quality products remains strong despite the global macroeconomic downturn.
Specifically, in the injectable aesthetics segment, growth was driven by neuromodulators, fillers, and biostimulants, which achieved double-digit growth in their key markets. In Europe, Galderma launched the first ready-to-use liquid botulinum toxin type A product, "Botox Alluzience®" in the first half of the year, to relieve moderate to severe frown lines between the eyebrows.
In terms of dermatological cosmetics, 8 out of the top 10 markets in this product category achieved double-digit growth. Cetaphil continued to perform strongly, driven by e-commerce and new product launches in China and other Asian markets, and buoyed by expansion in India and volume and revenue gains in the US. As for the products, it launched the Optimal Hydration line in Asia, including three new products powered by hyaluronic acid and the exclusive HydroSensitiv Complex for moisturizing and improving sensitive skin.
From a geographic perspective, markets achieved balanced net sales growth across all regions. On a constant currency basis, the US grew 14% year over year and the International Division grew 16% year-over-year, with accelerated growth in select markets such as China, India, and Brazil. In China, despite static management in certain cities due to COVID-19, Galderma maintained accelerated growth, achieving double-digit year-over-year performance growth in the injectable aesthetics and daily skincare segments.
In addition, in January, Galderma completed the acquisition of Alastin, a professional aesthetics company dedicated to developing innovative and clinically tested physician-dispensed skin care products. In the first half of the year, Alastin launched two new products, the one is ReFORM & RePAIR COMPLEX, an innovative formulation using TriHex Technology® to aid in surgical skin recovery, and another is HA Immerse Serum®, a new moisturizing hyaluronic acid formula that helps enhance the skin's natural ability to produce hyaluronic acid.
In the future, Galderma expects to achieve 12% to 14% year-over-year constant currency-based net sales and core EBITDA growth in 2022. Despite pressures such as inflation, it is confident that it will remain profitable due to significantly higher sales volumes, a pricing strategy based on product value, and high margins generated by new products that deliver significant consumer benefits.
Comentários